NO20062362L - Injiserbart implantat med langvarig frigjoring som har en bionedbrytende kjerne og en bionedbrytende hud - Google Patents

Injiserbart implantat med langvarig frigjoring som har en bionedbrytende kjerne og en bionedbrytende hud

Info

Publication number
NO20062362L
NO20062362L NO20062362A NO20062362A NO20062362L NO 20062362 L NO20062362 L NO 20062362L NO 20062362 A NO20062362 A NO 20062362A NO 20062362 A NO20062362 A NO 20062362A NO 20062362 L NO20062362 L NO 20062362L
Authority
NO
Norway
Prior art keywords
drug
core
skin
biodegradable
polymer
Prior art date
Application number
NO20062362A
Other languages
English (en)
Inventor
Hong Guo
Paul Ashton
Robert W Shimizu
David A Watson
Kang-Jye Chou
Original Assignee
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/714,549 external-priority patent/US8871241B2/en
Application filed by Psivida Inc filed Critical Psivida Inc
Publication of NO20062362L publication Critical patent/NO20062362L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Prostheses (AREA)

Abstract

En injiserbar legemiddeltilførselsinnretning inkluderer en kjerne inneholdende et eller flere legemidler og en eller flere polymerer. Kjernen kan være omgitt av et eller flere polymere ytre lag (referert heri som "belegg", "overtrekk" eller "ytre lag"). I visse utførelsesformer dannes innretningen ved å ekstrudere eller på annen måte å forhåndsforme et polymert overtrekk for en legemiddelkjerne. Legemiddelkjernen kan koekstruderes med overtrekket, eller innføres i overtrekket etter at overtrekket er blitt ekstrudert, og eventuelt herdet. I andre utførelsesformer kan legemiddelkjernen belegges med et eller flere polymerbelegg. Disse metoder kan med fordel anvendes for å produsere innretninger med en lang rekke forskjellige legemiddelformasjoner og overtrekk som kan velges til å kontrollere frigivelsestaktprofilen og forskjellige andre egenskaper av legemidlene i legemiddelkjernen i en form egnet for injeksjon ved bruk av nåler med standard eller ikke-standard nålestørrelse. Innretningen kan dannes ved å kombinere minst én polymer, minst ett legemiddel og minst ett flytende løsningsmiddel for å danne en flytende suspensjon eller oppløsning hvori etter injeksjon denne suspensjon eller oppløsning undergår en faseendring og danner en gel. Konfigurasjonen kan tilveiebringe styrt frigivelse av legemiddel eller legemidler over en forlenget periode.
NO20062362A 2003-11-13 2006-05-23 Injiserbart implantat med langvarig frigjoring som har en bionedbrytende kjerne og en bionedbrytende hud NO20062362L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/714,549 US8871241B2 (en) 2002-05-07 2003-11-13 Injectable sustained release delivery devices
US54336804P 2004-02-09 2004-02-09
PCT/US2004/035430 WO2005051234A2 (en) 2003-11-13 2004-10-26 Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin

Publications (1)

Publication Number Publication Date
NO20062362L true NO20062362L (no) 2006-08-13

Family

ID=34636703

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062362A NO20062362L (no) 2003-11-13 2006-05-23 Injiserbart implantat med langvarig frigjoring som har en bionedbrytende kjerne og en bionedbrytende hud

Country Status (19)

Country Link
EP (2) EP1696822B1 (no)
JP (3) JP5661226B2 (no)
AT (1) ATE460901T1 (no)
AU (1) AU2004292957C1 (no)
CA (1) CA2545650C (no)
CY (1) CY1114947T1 (no)
DE (1) DE602004026106D1 (no)
DK (1) DK1696822T3 (no)
ES (2) ES2447816T7 (no)
FR (1) FR14C0042I1 (no)
IL (1) IL175584A (no)
MX (1) MXPA06005431A (no)
NO (1) NO20062362L (no)
NZ (3) NZ575950A (no)
PL (2) PL1696822T3 (no)
PT (2) PT2233112E (no)
SI (1) SI1696822T1 (no)
TW (2) TWI445559B (no)
WO (1) WO2005051234A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
NZ575950A (en) 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
PL2155169T3 (pl) 2007-06-08 2016-09-30 Formulacja newirapiny o przedłużonym uwalnianiu
US9011361B2 (en) 2007-09-07 2015-04-21 Mati Therapeutics Inc. Lacrimal implant detection
FR2927798B1 (fr) * 2008-02-25 2011-03-04 C L Investissements Procede de fabrication d'un dispositif contraceptif intra-uterin et installation pour la mise en oeuvre de ce procede
US8858983B2 (en) 2009-04-30 2014-10-14 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
CA2795706A1 (en) * 2010-04-06 2011-10-13 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
EP2571526B1 (en) 2010-05-17 2019-03-13 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US8911427B2 (en) 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
JP2014508749A (ja) * 2011-02-11 2014-04-10 サイヴィーダ ユーエス，インコーポレイテッド 抗浮腫治療薬を使用する黄斑浮腫の治療方法
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EA201490500A1 (ru) 2011-08-30 2014-06-30 Университейт Гент Многослойный высвобождающий состав
US20130323306A1 (en) * 2012-05-30 2013-12-05 Boston Scientific Scimed, Inc. Injectable biodegradable particles for controlled therapeutic agent release
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
EP4537830A3 (en) 2017-06-13 2025-06-11 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
FR3085841B1 (fr) * 2018-09-14 2020-12-04 Oreal Procede de preparation de capsules et systeme associe
EP3698841A1 (en) * 2019-02-19 2020-08-26 L'oreal Injection device
EP4121017A4 (en) * 2020-03-17 2024-07-03 Blaesi, Aron H. EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR EXTENDED ACTIVE INGREDIENT RELEASE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5518672A (en) 1994-05-31 1996-05-21 Randcastle Extrusion Systems, Inc. Extrusion surge controller and method
US5486328A (en) 1994-05-31 1996-01-23 Randcastle Extrusion Systems, Inc. Extrusion surge suppressor and method
US5569429A (en) 1995-05-05 1996-10-29 Randcastle Extrusion Systems, Inc. Dynamic seal and sealing method
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
SE0001893D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab Medical arrangement
WO2003000156A1 (en) * 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
WO2003051328A1 (en) * 2001-12-18 2003-06-26 Novo Nordisk A/S Solid dose micro implant
NZ575950A (en) 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin

Also Published As

Publication number Publication date
SI1696822T1 (sl) 2010-07-30
AU2004292957C1 (en) 2011-04-28
PL1696822T3 (pl) 2010-08-31
AU2004292957A1 (en) 2005-06-09
EP2233112A2 (en) 2010-09-29
TWI496597B (zh) 2015-08-21
DK1696822T3 (da) 2010-05-17
HK1148931A1 (en) 2011-09-23
MXPA06005431A (es) 2007-01-25
FR14C0042I1 (fr) 2014-06-27
EP2233112A3 (en) 2011-03-02
DE602004026106D1 (de) 2010-04-29
JP2012072180A (ja) 2012-04-12
AU2004292957B2 (en) 2010-09-09
ES2447816T7 (es) 2014-06-25
WO2005051234A2 (en) 2005-06-09
TWI445559B (zh) 2014-07-21
PT2233112E (pt) 2014-02-27
NZ547619A (en) 2009-06-26
JP5526114B2 (ja) 2014-06-18
NZ581461A (en) 2011-04-29
ATE460901T1 (de) 2010-04-15
IL175584A (en) 2015-05-31
JP5918195B2 (ja) 2016-05-18
JP5661226B2 (ja) 2015-01-28
ES2340389T3 (es) 2010-06-02
PT1696822E (pt) 2010-04-28
EP2233112B1 (en) 2013-11-20
EP1696822A2 (en) 2006-09-06
PL2233112T3 (pl) 2014-05-30
TW200526285A (en) 2005-08-16
CA2545650A1 (en) 2005-06-09
ES2447816T3 (es) 2014-03-13
CA2545650C (en) 2015-08-18
TW201422269A (zh) 2014-06-16
EP1696822B1 (en) 2010-03-17
JP2007512248A (ja) 2007-05-17
IL175584A0 (en) 2006-09-05
CY1114947T1 (el) 2016-12-14
NZ575950A (en) 2010-06-25
JP2014040479A (ja) 2014-03-06
EP2233112B3 (en) 2014-05-14
WO2005051234A3 (en) 2005-11-10
PL2233112T6 (pl) 2014-11-28

Similar Documents

Publication Publication Date Title
NO20062362L (no) Injiserbart implantat med langvarig frigjoring som har en bionedbrytende kjerne og en bionedbrytende hud
Flynn et al. Fiber templating of poly (2-hydroxyethyl methacrylate) for neural tissue engineering
Johnson et al. Drug eluting implants in pharmaceutical development and clinical practice
CY1122304T1 (el) Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων
WO2010042205A3 (en) Methods of making biocomposite medical constructs and related constructs including artificial tissues, vessels and patches
MXPA05014193A (es) Fomas de dosis de liberacion sostenida de anestesicos para el manejo del dolor.
WO2008139786A1 (ja) 微細針ディバイス及びその製造方法
US20190030309A1 (en) Method for manufacturing microneedle by using biocompatible polymer
ATE421316T1 (de) Herstellung von langzeit- arzneimittelabgabevorrichtungen mit polymeren auf polyurethanbasis
WO2007041410A3 (en) Sustained release small molecule drug formulation
CN104135954B (zh) 膜及制造方法
UA106593C2 (uk) Пристрій для пролонгованого введення ліків, який містить полімери на основі поліуретану, та спосіб його виготовлення
DE60231862D1 (de) Erodierbare polymere zur injektion
NO20025759D0 (no) Formulering basert på heparin, glykosaminoglykan eller heparinoid, anvendelse av formuleringen og formuleringsbasen
DE60017956D1 (de) Biodegradierbare polymerzusammensetzung
NZ600921A (en) Intraocular drug delivery systems
ATE373018T1 (de) Esterderivate von hyaluronsäure zur herstellung von hydrogelmaterialien durch photohärtung
Pothupitiya et al. Synthetic biodegradable polyesters for implantable controlled-release devices
Silvestre et al. Microneedle arrays of polyhydroxyalkanoate by laser-based micromolding technique
IN2012DN04939A (no)
KR101697556B1 (ko) 마이크로 구조체 제조장치, 제조방법 및 이로부터 제조된 마이크로 구조체
Mazzocchi et al. A Novel Approach for Multiple Material Extrusion in Arthroscopic Knee Surgery
WO2006084211A3 (en) Thermoplastic articles containing a medicament
Morde Micro-3D printing of bio-inspired microneedle with enhanced adhesion capabilities
Madhaparia 3D Printing of a Biocompatible Scaffold and a Real-Time Imaging Window for Monitoring Rat Spinal Cord Regeneration